FTC Will Have Opportunity To Address Genomics In Review Of Glaxo/SB
The Glaxo SmithKline merger will provide an opportunity for antitrust regulators to weigh in on the commercial exploitation of the human genome.
The Glaxo SmithKline merger will provide an opportunity for antitrust regulators to weigh in on the commercial exploitation of the human genome.